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ABSTRACT
Background: Pneumonia is the most common cause of death in children worldwide, accounting 
for 15% of all deaths of children under 5 years of age. This review summarises the evidence for 
the empirical antibiotic treatment of community-acquired pneumonia in neonates and children 
and puts emphasis on publications since the release of the previous WHO Evidence Summary 
report published in 2014.
Methods: A systematic search for systematic reviews and meta-analyses of antibiotic therapy 
for community-acquired pneumonia was conducted between 1 January 2013 and 10 November 
2016.
Results:  The optimal dosing recommendation for amoxicillin remains unclear with limited 
pharmacological and clinical evidence. There is limited evidence from surveillance to indicate 
whether amoxicillin or broader spectrum antibiotics (e.g. third-generation cephalosporins) are 
being used most commonly for paediatric CAP in different WHO regions. Data are lacking on 
clinical efficacy in the context of pneumococcal, staphylococcal and mycoplasma disease and 
the relative contributions of varying first-line and step-down options to the selection of such 
resistance.
Conclusion:  Further pragmatic trials are required to optimise management of hospitalised 
children with severe and very severe pneumonia.
Abbreviations: AAD, antibiotic-associated diarrhoea; BNFc, British National Formulary for 
Children; BTS, British Thoracic Society; CAP, community-acquired pneumonia; CPS, Canadian 
Paediatric Society; EARS-Net, European Antimicrobial Resistance Surveillance Network; ESPID, 
European Society for Paediatric Infectious Diseases; GRADE, Grading of Recommendations 
Assessment, Development and Evaluation; IDSA, Infectious Diseases Society of America; IMCI, 
integrated management of childhood illness; PCV, pneumococcal conjugate vaccine; PIDS, 
Pediatric Infectious Diseases Society; RCPCH, Royal College of Paediatrics and Child Health; 
WHO, World Health Organization
Introduction
This review summarises the most up-to-date evidence 
for the empirical antibiotic treatment of community-ac-
quired pneumonia (CAP) in neonates and children. For 
this update, special emphasis has been placed on publi-
cations since the release of the previous report ‘Revised 
WHO Classification and Treatment of Pneumonia in 
Children at Health Facilities: Evidence Summaries’ in 2014 
[1]. As the 2014 guideline was both recent and a major 
revision of guidance, this review summarises the recent 
literature and discusses emerging challenges.
CAP refers to pneumonia acquired in the commu-
nity. Pneumonia accounts for 15% of all deaths of chil-
dren <5 years of age and is the single largest infectious 
cause of death in children worldwide. In HIV-uninfected 
children, pneumococcal infection is responsible for 
around 11% of all deaths in this age group [1]. Nearly, 
1 in 500 children under the age of 5 years is hospital-
ised each year with CAP [2]. However, only 54% of chil-
dren with symptoms of pneumonia are taken outside 
the home for care [3]. Pneumonia affects children and 
families everywhere, but is most prevalent in South Asia 
and sub-Saharan Africa [1]. There are signs of progress 
in the 75 countries included in ‘Countdown to 2015’ [3]. 
In this group, the number of deaths from pneumonia 
in children under 5 has declined from 21% in 2000 to 
16% in 2015 [3]. Nonetheless, CAP remains an issue of 
profound economic and social importance to children 
and communities worldwide.
Aetiological studies of CAP in children are complicated 
by the low yield of blood cultures, inadequate sputum 
specimens and infrequent work-up with lung aspiration 
and broncho-alveolar lavage. Quantification of aetiol-
ogy is further complicated by limited microbiological 
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updating the classification of pneumonia severity and 
changing the recommendation for first-line antibiotics [1].
The 2014 guidance reclassified CAP requiring treat-
ment at a healthcare facility into three categories: very 
severe pneumonia, severe pneumonia and non-severe 
pneumonia. The new approach was designed to simplify 
the management of pneumonia at the outpatient level, 
reduce the number of referrals for hospitalisation and 
achieve better treatment outcomes.
Very severe pneumonia is defined as cough or diffi-
culty breathing plus any of the following: central cyano-
sis; inability to breastfeed, drink, or vomiting everything; 
convulsions, lethargy, or unconsciousness; and severe 
respiratory distress. Severe pneumonia is defined as 
cough or difficulty breathing and one of the following: 
lower chest-wall indrawing; nasal flaring; grunting (in 
young infants) with no signs of very severe pneumonia, 
especially if <2 months of age.
Non-severe pneumonia is defined as cough or diffi-
culty breathing accompanied by tachypnoea (respiratory 
rate ≥50 breaths/minute in infants aged 2–11 months, 
≥40 breaths/minute in children aged 12–59 months) with 
no signs of severe or very severe pneumonia, especially if 
aged ≥2 months. The WHO definition of treatment failure 
includes development of signs of severe or very severe 
pneumonia and persistently raised respiratory rate at 
72 h (48 h in areas with a high prevalence of HIV).
Previous to the 2014 revision, four treatment cate-
gories were defined for CAP. Children with ‘fast breath-
ing’ pneumonia were treated with oral cotrimoxazole. 
Children with ‘chest indrawing’ pneumonia were referred 
to a healthcare facility and treated with injectable pen-
icillin/ampicillin. As a result of new evidence, the 2014 
revision preferred oral amoxicillin to oral cotrimoxazole 
for the treatment of fast-breathing pneumonia and was 
equivalent to injectable penicillin/ampicillin in cases of 
chest-indrawing pneumonia. Since both fast-breathing 
and chest-indrawing pneumonias were now best treated 
with amoxicillin, classifications were also revised. The 
new classification was revised to include only two cat-
egories of pneumonia: ‘pneumonia’ with fast breathing 
and/or chest indrawing, which requires home therapy 
with oral amoxicillin, and ‘severe pneumonia’, pneumonia 
with any general danger sign, which requires referral and 
injectable antibiotic therapy.
Summary of international guidelines
Recently published international clinical practice guide-
lines were also reviewed. These included clinical practice 
guidelines in the British National Formulary for Children 
(BNFc) [8], the Royal College of Paediatrics and Child 
Health (RCPCH) [9], the European Society for Paediatric 
Infectious Diseases (ESPID) [10], the Canadian Paediatric 
Society (CPS) [11], the British Thoracic Society (BTS) [7] 
and the Pediatric Infectious Diseases Society (PIDS) [12]. 
These have been summarised in Table 1.
work-up in the community, seasonality, mixed infections 
and viruses and commensal bacteria in samples.
Streptococcus pneumoniae is widely considered to be 
the leading cause of CAP, though proportions vary by 
region. It is responsible for about one-third of radiolog-
ically confirmed pneumonia in children aged <2 years. 
S. pneumoniae is commonly found in asymptomatic 
nasopharyngeal carriage. The asymptomatic carriage 
state is responsible for much of the transmission within 
populations, such as day-care centres [4]. Haemophilus 
influenzae type b (Hib) is a major pathogen, though 
proportions vary regionally and with vaccine cover-
age [5]. Pneumonia caused by Mycoplasma pneumo-
niae is considered an atypical bacterial pneumonia 
because of its different course, radiological findings 
and treatment. Active population-based surveillance 
for CAP was undertaken in hospitals in three American 
cities [6]. The annual incidence of hospitalisation for 
pneumonia was 15.7 cases per 10,000 children (95% CI 
14.9–16.5). The annual incidence of M. pneumoniae was 
1.4/10,000 (95% CI 1.2–1.6) and of S. pneumoniae was 
0.5/10,000 (95% CI 0.4–0.6) [6]. Less commonly, severe 
infection is caused by Staphylococcus aureus, especially 
following influenza. Fungal infection by Pneumocystis 
jiroveci (PJP) is particularly important in young children 
with AIDS. Furthermore, children with milder atypical 
pathogens may recover without antibiotic interven-
tion. Causative pathogens also vary with age. Overall, 
viruses alone are a cause in younger children, in up 
to 50%. When a bacterial cause is found in older chil-
dren, it is most commonly S. pneumoniae, followed by 
M. pneumoniae [7].
One-third of cases of CAP are a mixed infection 
with viruses and bacteria [7]. Viruses commonly asso-
ciated with CAP are respiratory syncytial virus (RSV), 
 para-influenza and influenza. Other viruses isolated in 
children with pneumonia include adenovirus, rhinovi-
rus, herpes simplex virus, enteroviruses, human metap-
neumovirus, human bocavirus and coronavirus. Overall, 
viruses account for 30–67% of childhood CAP and are 
more frequently identified in children aged <1 year than 
in those aged >2 years [7].
Current WHO guidelines and rationale
The ‘Revised WHO Classification and Treatment of 
Pneumonia in Children at Health Facilities: Evidence 
Summaries’ was published in 2014 [1]. The revision 
integrated input from two consultations which used 
the GRADE approach (Grading of Recommendations 
Assessment, Development and Evaluation): the 2010 WHO 
Recommendations on the Management of Diarrhoea 
and Pneumonia in HIV-infected Infants and Children: 
Integrated Management of Childhood Illness (IMCI) and 
the 2012 Recommendations for Management of Common 
Childhood Conditions, Evidence for Technical Update of 
Pocket Book Recommendations. The revisions include 
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clinical trial (NCT02891915) to test the effectiveness 
of short (5-day) vs standard (10-day) course therapy 
in children diagnosed with CAP and initially treated in 
outpatient clinics, urgent care facilities and emergency 
departments [16]. The primary objective is to compare 
the composite overall outcome (Desirability of Outcome 
Ranking, DOOR) in children with CAP aged 6–71 months 
assigned to a strategy of short course (5 days) vs stand-
ard course (10  days) outpatient β-lactam therapy at 
Outcome Assessment Visit 1 (Study Day 8 ± 2 days). The 
study commenced in October 2016 and the completion 
date is March 2019 with an estimated enrollment of 400 
patients.
A Malaysian trial (NCT02258763) in children hospi-
talised with pneumonia is being conducted to deter-
mine whether an extended duration of oral antibiotics 
(10 days) is better for improving clinical outcomes than 
a shorter duration (3 days) of antibiotics [17]. Patients in 
the experimental arm will receive amoxicillin-clavulanate 
22.5 mg/kg/dose bd for 10 days, while the comparator 
arm will receive amoxicillin-clavulanate 22.5 mg/kg/bd 
for 3 days followed by another 7 days of placebo given 
at the same dose and frequency. The study began in 
November 2014, aiming to enrol 300 patients, and the 
estimated completion date is December 2018.
Two clinical trials investigating amoxicillin in child-
hood pneumonia are being conducted in Malawi. In a 
trial (NCT02760420) sponsored by Save the Children, the 
effectiveness of no antibiotic treatment for fast-breath-
ing CAP is being compared with amoxicillin therapy 
[18]. Patients in the placebo arm will be given 250 mg of 
placebo (dispersible tablet) in two divided doses based 
on age bands (500  mg/day for children 2–12  months, 
1000  mg/day for children 12  months to 3  years, and 
1500 mg/day for children 3–5 years of age). The active 
comparator arm will receive 3 days of 250 mg amoxicillin, 
dispersible tablet (DT) in two divided doses based on age 
bands (500 mg/day for children 2–12 months, 1000 mg/
day for children 12  months to 3  years, and 1500  mg/
day for children 3–5 years). The estimated enrollment is 
2000 patients with the study running from June 2016 to 
September 2018.
In the same setting, another trial (NCT02678195) 
will compare 3 vs 5 days of treatment for chest-indraw-
ing pneumonia [19]. The experimental arm will receive 
3  days of amoxicillin and 2  days of placebo while the 
comparator arm will receive 5 days of amoxicillin. The 
study aimed to run from March 2016 to August 2018 with 
an estimated enrollment of 2000 patients.
A one-arm safety intervention (NCT02878031) in 
Nigeria will evaluate the role of community manage-
ment of chest-indrawing pneumonia with oral amox-
icillin [20]. The primary objective is to assess whether 
community health workers can safely and appropriately 
manage chest-indrawing pneumonia in children aged 
2–59 months and refer children with danger signs. The 
Methods
A systematic search for systematic reviews and 
meta-analyses of antibiotic therapy for CAP published 
in English between 1 January 2013 to 10 November 2016 
was undertaken. MEDLINE, the Cochrane Database for 
Systematic Reviews and ClinicalTrials.gov were searched. 
The search strategy of databases focused on clinical tri-
als, controlled clinical trials, reviews or systematic reviews 
in all children (0–18 years). The search was conducted 
on 10 November 2016 combining MeSH and free-text 
terms ‘community-acquired infections’, ‘pneumonia, bac-
terial’, ‘community-acquired pneumonia’, ‘antibiotics’ and 
‘anti-bacterial agents’. PubMed was searched for relevant 
guidelines. Titles and abstracts, full texts and subsequent 
data abstraction were screened independently, followed 
by consensus discussion.
Results
On-going clinical trials
Several clinical trials of antibiotics for CAP are registered 
on ClinTrialsGov.
A study in Beijing Children’s Hospital (NCT02775968) 
is investigating the population pharmacokinetics of 
cephalosporins and macrolide antibiotics for CAP in chil-
dren, aiming to correlate it with treatment effectiveness 
and the incidence of adverse effects [13]. The study com-
menced in August 2016 with an estimated enrollment 
of 750 children and a completion date of October 2022.
A phase 2/3, randomised, open-label, active control, 
multi-centre study (NCT02605122) to assess the safety 
and efficacy of solithromycin in children and adolescents 
with CAP is being conducted under the sponsorship of 
Cempra Inc. [14]. Solithromycin will be compared with 
the standard of care for an estimated enrollment of 400 
patients. The study commenced in March 2016 with an 
estimated completion date of January 2018.
A Canadian randomised, controlled, double-blind, 
non-inferiority clinical trial (NCT02380352) will deter-
mine whether 5 days of high-dose amoxicillin leads to 
comparable rates of early clinical cure compared with 
10 days of high-dose amoxicillin for previously healthy 
children with mild CAP [15]. In the experimental arm, 
patients will be given 5 days of amoxicillin 90 mg/kg/
day in three divided doses, followed by 5 days placebo 
three times a day. The active comparator arm will be 
given 5 days amoxicillin 90 mg/kg/day in three divided 
doses, followed by alternate formulation 5 days amox-
icillin 90  mg/kg/day in three divided doses. The esti-
mated enrollment for the study is 270 patients and it 
commenced in March 2016 with a completion date of 
May 2018.
The National Institute of Allergy and Infectious 
Diseases (NIAID) is sponsoring a multi-centre, ran-
domised, double-blind, placebo-controlled, superiority 
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(6/29) and 22% (2/9), respectively. Ceftaroline fosamil 
was well tolerated and the clinical response rates were 
similar to that of ceftriaxone plus vancomycin.
New interventions
Several interventions are complementary to antibiotic 
therapy for the management of CAP. Successful efforts 
are being made to integrate management and global 
vaccination campaigns.
The WHO Integrated Global Action Plan for the 
Prevention and Control of Pneumonia and Diarrhoea 
(GAPPD) aims to address protection, prevention and 
treatment of pneumonia and diarrhoea through inte-
grated programmes in low- and middle-income coun-
tries (LMIC) [25]. Several identified interventions are 
specific to pneumonia, e.g. reduced household air pol-
lution; pneumococcal conjugate vaccine (PCV), Hib and 
pertussis vaccination; and oxygen therapy when availa-
ble. However, several interventions have been identified 
which are complementary for both pneumonia and diar-
rhoea. These are categorised as protect (breastfeeding 
promotion and support, adequate complementary feed-
ing), prevent (measles vaccination, handwashing with 
soap, prevention of HIV) and treat (improving care-seek-
ing behaviour and referral, improved case management 
at community and health facility levels, and continued 
feeding).
In the 2011–2015 strategic period, the Global Alliance 
for Vaccines and Immunization (GAVI) introduced PCV to 
51 countries including Bangladesh, Cambodia, Eritrea, 
Guinea Bissau, Lesotho, Nepal, Solomon Islands and 
Uzbekistan [26]. To date, it is estimated that, with GAVI 
support, over 76 million children have received PCV. 
However, coverage with the third dose of vaccine was 
only 35% in 2015.
New efficacy data
The KEMRI–Wellcome Trust Collaborative Research 
Programme conducted a trial (NCT01399723) to assess 
whether clinical outcome following initial treatment with 
oral amoxicillin for severe pneumonia is as effective as 
the current standard benzyl penicillin [27]. The open-la-
bel, multi-centre, randomised controlled non-inferiority 
trial of the treatment of severe pneumonia recruited 527 
children aged 2–59 months in six Kenyan hospitals. The 
children were randomised to receive amoxicillin or ben-
zyl penicillin and were followed up for the primary out-
come of treatment failure at 48 h. The treatment failed 
in 20 of 260 (7.7%) and 21 of 261 (8.0%) patients in the 
amoxicillin and benzyl penicillin arms, respectively (RD 
−0.3%, 95% CI −5.0 to 4.3%), confirming the non-inferi-
ority of amoxicillin to benzylpenicillin.
In the IndiaCLEN multi-centre trial (NCT01386840), 
the safety and efficacy of oral amoxicillin for severe 
aim was to include approximately 308 children aged 
2–59 months with chest-indrawing pneumonia and the 
study was conducted between October 2016 and July 
2017.
In a double blind efficacy study entitled RETAPP 
(NCT02372461), investigators based at Aga Khan 
University, Karachi compared standard amoxicillin treat-
ment with placebo in poor urban slum settings in South 
Asia [21]. The study ran from November 2014 to July 2017 
with an enrolment of 2500 patients.
Investigators in the United Kingdom are initiating a 
multi-centre, randomised, double-blind placebo-con-
trolled 2  ×  2 factorial non-inferiority trial of amoxicil-
lin dosage and duration in paediatric CAP (CAP-IT) 
(ISRCTN76888927) [22]. The efficacy, safety and impact 
on antimicrobial resistance related to the duration 
and dosage of amoxicillin will be assessed in children 
aged 1–5 years presenting to the Emergency Room or 
Paediatric Assessment Unit with a clinical diagnosis of 
CAP in whom the decision has been made to treat with 
antibiotics. Participants will be randomised to four treat-
ment groups: shorter course and lower dose (3 days of 
35–50 mg/kg/day), longer course and lower dose (7 days 
of 35–50  mg/kg/day), shorter course and higher dose 
(3  days of 70–90  mg/kg/day), and longer course and 
higher dose (7 days of 70–90 mg/kg/day). They expect 
to recruit 2400 over the 2 years from March 2016 to May 
2018.
New antibiotics
Ceftaroline fosamil is a broadspectrum cephalosporin 
antibiotic with activity against many bacteria, includ-
ing S. pneumoniae (both penicillin-non-susceptible and 
multi-drug-resistant strains) and S. aureus (including 
methicillin-resistant S. aureus) [23]. In a phase 2/3 study 
(NCT01530763), 160 paediatric patients hospitalised 
with CAP received either intravenous ceftaroline fosa-
mil or ceftriaxone in a randomised, active-controlled, 
observer-blinded clinical trial. The effectiveness of cef-
taroline fosamil was similar to that of ceftriaxone, with 
high clinical cure rates at test of cure in the modified 
intention-to-treat population (94/107; 88% and 32/36; 
89%, respectively). Three documented S. aureus infec-
tions were successfully treated in the ceftaroline group, 
including one caused by methicillin-resistant S. aureus. 
In the phase 4 study (NCT01669980), the safety and 
effectiveness of ceftaroline fosamil in children was eval-
uated in a multi-centre, randomised, observer-blinded, 
active-controlled trial[24]. Ceftaroline fosamil was com-
pared with intravenous ceftriaxone plus vancomycin 
in patients aged between 2 months and 17 years with 
complicated CAP. Clinical response rates in the modified 
intention-to-treat population were 52% (15/29 patients) 
in the ceftaroline fosamil group and 67% in the compar-
ator group (6/9); clinical stability at Study Day 4 was 21% 
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of WHO-defined very severe/severe/non-severe CAP 
were included. Study participants included children 
aged 2–59 months with CAP. Twenty-two studies which 
enrolled 20,593 children were included in meta-analyses. 
A combination of penicillin/ampicillin and gentamicin 
was effective for very severe pneumonia, and oral amoxi-
cillin was as effective as other parenteral antibiotics. Oral 
amoxicillin was also found to be effective in non-severe 
pneumonia. The review further found that a short 3-day 
course of antibiotics was as beneficial as 5-day course for 
non-severe pneumonia in children aged 2–59 months.
A systematic review and expert survey review iden-
tified several candidate predictors of oral antibiotic fail-
ure not currently used in childhood pneumonia referral 
algorithms; they included excess age-specific respira-
tory rate, young age, abnormal oxygen saturation and 
moderate malnutrition in children aged 2–59 months in 
resource-limited settings with WHO-defined non-severe 
pneumonia (fast breathing for age and/or lower chest-
wall indrawing without danger signs) [31] . In nine stud-
ies which met the inclusion criteria, oral antibiotic failure 
rates ranged between 7.8 and 22.9%. Six studies found 
excess age-adjusted respiratory rate — defined either 
as WHO-defined very fast breathing for age or 10–15 
breaths/min faster than normal WHO age-adjusted 
thresholds (<50 breaths/min for ages 2–11  months 
and <40 breaths/min for ages 12–59 months — and four 
studies reported young age to be predictive of failure of 
oral antibiotics [31].
The question of the M. pneumoniae spectrum, specif-
ically macrolide use in CAP, is commonly encountered 
in paediatric practice. A meta-analysis of children with 
community-acquired lower respiratory tract infection 
treated specifically for M. pneumoniae was undertaken 
[32]. Sixteen articles detailing 17 studies were included. 
Several low-quality studies found a reduction in fever 
duration but the clinical impact of this effect was 
unclear. Meta-analysis of five randomised controlled 
trials showed a pooled risk difference of 0.12 (95% CI 
0.04–0.20) favouring treatment with macrolides, tetracy-
clines or quinolones class antibiotics which was not sta-
tistically significant. Overall, the authors considered that 
there is insufficient evidence to support any conclusion 
about the efficacy of macrolides for M. pneumoniae CAP 
in children. Future studies should highlight the potential 
for confounding mixed infections, timing of intervention 
relative to symptom onset, and testing modalities that 
include a combination of serology and polymerase chain 
reaction assays.
Discussion
The high prevalence of CAP in children means that clini-
cians and public health experts face on-going challenges 
in prescribing antibiotics for children. These challenges 
frame the appraisal of evidence and guide antibiotic 
choice.
pneumonia at home or in hospital were compared [28]. 
This open-label, multi-centre, prospective, two-arm, 
randomised clinical trial in children aged 3–59 months 
with severe pneumonia aimed to determine the differ-
ences in treatment failure between a 7-day course of 
oral amoxicillin for the first 48 h in hospital and being 
sent home on the same treatment after enrolment. A 
total of 1118 children were enrolled and randomised to 
the home (n = 554) or hospital group (n = 564). Overall 
treatment failure rate was 11.5% (per protocol analysis) 
[28]. In the intention-to-treat analysis, treatment was sig-
nificantly more likely to fail in the hospital group than in 
the home group. Death rates at 7 or 14 days did not differ 
significantly (RD 0.0%, 95% CI −0.5 to 0.5). The median 
total treatment cost was INR 399 for the home group and 
INR 602 for the hospital group (p < 0.001) for the same 
5% failure rate after 7 days of treatment in the random 
sub-sample. Home-based treatment with oral amoxicillin 
was equivalent to hospital treatment for the first 48 h in 
children with chest-indrawing pneumonia and was less 
expensive.
A Cochrane review examined antibiotics for CAP in 
children and made recommendations for countries with 
high case fatalitie rates owing to pneumonia in children 
without underlying morbidities and where point-of-care 
tests for identifying aetiological agents for pneumonia 
were not available [29]. Twenty-nine trials comparing 
multiple antibiotics to which 14,188 children had been 
enrolled were included. For non-severe CAP in ambula-
tory settings, amoxicillin compared with co-trimoxazole 
had similar failure rates (OR 1.18, 95% CI 0.91–1.51) and 
cure rates (OR 1.03, 95% CI 0.56–1.89). In children with 
severe pneumonia without hypoxaemia, oral antibiotics 
(amoxicillin/co-trimoxazole) compared with injectable 
penicillin had similar failure rates (OR 0.84, 95% CI 0.56–
1.24), hospitalisation rates (OR 1.13, 95% CI 0.38–3.34) 
and relapse rates (OR 1.28, 95% CI 0.34–4.82). In very 
severe CAP, death rates were higher in children receiv-
ing chloramphenicol than in those receiving penicillin/
ampicillin plus gentamicin (OR 1.25, 95% CI 0.76–2.07). 
Based on these findings, amoxicillin was recommended 
over co-trimoxazole for patients with CAP in ambulatory 
settings, with amoxicillin clavulanate and cefpodoxime 
as alternative second-line drugs. Oral amoxicillin was rec-
ommended for children in an ambulatory setting with 
severe pneumonia without hypoxaemia. For children 
hospitalised with severe and very severe CAP, penicil-
lin/ampicillin plus gentamicin was superior to chloram-
phenicol. The other alternative drugs for such patients 
are amoxicillin clavulanate and cefuroxime.
A meta-analysis of trials in LMICs was undertaken 
to determine the most suitable antibiotic therapy for 
treating pneumonia (very severe, severe and non-se-
vere) and examined type of drug, duration of illness 
and combination therapy [30]. Randomised controlled 
trials and quasi-RCTs that assessed the route, dose, com-
bination and duration of antibiotics in the management 
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the pneumococcal isolates reported to the European 
Antimicrobial Resistance Surveillance Network (EARS-
Net). A large majority of isolates from serogroups 1, 3 
and 7 were susceptible to penicillin and macrolides. 
For serogroup 19, 52% of the isolates had decreased 
susceptibility to penicillin and/or macrolides [35].
For countries reporting to EARSnet for 2014, sero-
groups 1 and 19 were the most prevalent (accounting 
for 13.2 and 12.8% of isolates, respectively), followed by 
serogroup 7 (11.9%) and serogroup 3 (8.6%). Among the 
most commonly reported serogroups, dual non-suscep-
tibility to penicillin and macrolides was mainly observed 
in serogroups 19, 14, and 6 (by order of decreasing per-
centage). Single non-susceptibility to penicillins was 
most common in serogroups 19, 14 and 9, and single 
non-susceptibility to macrolides was most common in 
serogroups 19, 1, 14 and 6 [35].
The efficacy of pneumococcal conjugate vaccine 
(PCV13) was assessed by comparing rates of invasive 
pneumococcal disease in children before and after 
the introduction of PCV13 in the United States [34]. A 
time-series model was used to compare the reported 
incidence of invasive pneumococcal disease (IPD) to 
that which would have been expected if PCV13 had not 
replaced PCV7. The authors determined that the over-
all incidence of IPD declined by 64% (95% CI 59–68), 
and that IPD caused by PCV13 minus PCV7 serotypes 
declined by 93% (95% CI 91–94). It was estimated that 
over 30,000 cases of IPD and 3000 deaths were averted 
in the first 3 years after introduction of PCV13 [36].
The effectiveness of the PCV13 vaccine was further 
assessed in a matched case-control study [37]. A total 
of 722 cases of invasive pneumococcal disease in chil-
dren aged 2–59 months were identified through active 
surveillance in 13 sites; 2991 controls were identified in 
birth registries and matched to cases by age and post 
code. PCV13 serotype cases (30%) included most com-
monly identified serotypes 19A (18%), 7F (4%) and 3 
(6%). Vaccine effectiveness against all PCV13 serotypes 
was 86% (95% CI 75.5–92.3), 85.6% (95% CI 70.6–93.5) for 
serotypes 19A and 96.5% (95% CI 82.7–100.0) for sero-
type 7F. The effectiveness against serotype 3 (79.5%, 95% 
CI 30.3–94.8) and antibiotic non-susceptible invasive 
pneumococcal disease (65.6%, 95% CI 44.9–78.7) was 
statistically significant. Vaccine effectiveness against all-
cause invasive pneumococcal disease was 60.2% (95% CI 
46.8–70.3) and was similar in children with (81.4%, 95% CI 
45.4–93.6) and without (85.8%, 95% CI 74.9–91.9) under-
lying conditions.
Invasive pneumococcal isolates recovered from 
children aged < 5 years through Active Bacterial Core 
surveillance were analysed before (2008–2009, n = 828) 
and after (2011–2013, n = 600) the implementation of 
the 13-valent pneumococcal conjugate vaccine (PCV13) 
[36]. PCR/electrospray ionisation mass spectrometry and 
whole genome sequence (WGS) analysis was used to 
Antibiotic dosing plays an important role in adverse 
events and, in turn, compliance with treatment. 
Antibiotic-associated diarrhoea (AAD) is a well-rec-
ognised adverse reaction to amoxicillin. A review of 
reported rates of AAD following oral penicillin treatment 
in paediatric clinical trials quantified the evidence and 
elucidated the dearth of strong evidence in this field [33]. 
Of 7729 paediatric patients, 17.9% had AAD. For amox-
icillin, the pooled rate in six studies was 8.1% (range 
1.87–17.5%). However, there was no demonstrable cor-
relation between the dose of amoxicillin and the rate of 
AAD. Importantly, there was an association between age 
and diarrhoea related to oral penicillin. Younger children 
aged 1 month to 2 years experienced higher rates of ADD 
(18%) than children aged 2–7 (4%) and those older than 
7 years (2%). While it is important to consider AAD, the 
precise mechanism and robust evidence of a dose-to-
AAD rate response remains to be demonstrated. Further 
work is required to assess the role of dose and duration 
on AAD rates and to include diarrhoea using a standard-
ised definition as an outcome measure in randomised 
controlled trials.
Changing epidemiology
Issues of surveillance. Globally, there are difficulties in 
surveillance of antimicrobial resistance (AMR) owing 
to limited laboratory capacity, harmonised diagnostic 
procedures and a lack of surveillance networks. Mapping 
AMR in under-resourced countries requires focus on 
specimen shipping conditions, data standardisation, 
absence of contamination and adequate diagnostics 
[34].
When considering available data on S. pneumoniae 
in resource-limited settings, the extent of outpatient 
penicillin use correlates with the degree of resistance 
of invasive isolates. In a surveillance study of hospital-
ised patients in 11 Asian countries, high-level penicillin 
resistance was much lower than levels of resistance to 
erythromycin (72.7%) and multi-drug resistance (59.3%). 
In South Africa, 18% of 20,100 isolates of S. pneumoniae 
identified were resistant to three typical antibiotics. 
However, it is important to note that AMR data often 
come from hospitals attended by wealthy patients, 
introducing bias. Furthermore, it is important that sur-
veillance of pneumococcal pathogens integrates the 
effects of other public health measures such as conju-
gate vaccinations [34].
Effect of PCV13 vaccine on serotype selection. The 
widespread use of pneumococcal vaccines is altering 
the landscape of resistance. Infections and paediatric 
carriage has been reduced in classically resistant 
serotypes (14, 6B, 19F, 23F) which are covered 
by currently available multivalent PCV vaccines. 
Serogroups 1, 3, 7 and 19 were the most common of 
PAEDIATRICS AND INTERNATIONAL CHILD HEALTH  S73
outcomes similar to or better than those with traditional 
longer durations were identified. The minimum intrave-
nous antibiotic duration was less than one day, and, for 
severe or complicated CAP, initial intravenous treatment 
was recommended based on expert opinion. The crite-
rion for switch to oral antibiotic was clinical improve-
ment. The minimum total antibiotic duration was 3 days 
for mild CAP and fewer than or equal to 7 days for mod-
erate or severe uncomplicated CAP. Oral antibiotics were 
deemed acceptable for most children requiring hospital 
admission.
A Cochrane review examined randomised con-
trolled trials which evaluated the efficacy of a 
short-course (2–3  days) vs a long-course (5  days) of 
intravenous antibiotic therapy for severe pneumonia 
in children aged 2–59  months. Children with debili-
tating disease, HIV infection, very severe pneumonia 
and nosocomial pneumonia were excluded. A total 
of 2352 studies were identified, but none fulfilled the 
inclusion criteria.
In conclusion, the data presented above demonstrates 
that there is no evidence to recommend amending the 
current 2014 ‘Revised WHO Classification and Treatment of 
Childhood Pneumonia at Health Facilities’, either in terms of 
drug choice, dosing or duration. Recent systematic reviews 
support the 2014 recommendations and no new trial evi-
dence counters this view. This review has not focussed 
on recent aetiology studies, or other data on advances 
in molecular diagnostics (e.g. pneumococcal DNA load) 
predicting viral or bacterial respiratory infection. A number 
of CAP amoxicillin trials are underway comparing varying 
dose and duration regimens, although there has been lim-
ited harmonisation as yet of study design. Not all of these 
trials may be relevant to the LMIC setting. Few trials as 
yet are including AMR outcomes, making assessment of 
optimal treatment recommendations at a population level 
from an AMR perspective currently not possible. There is a 
major need for further trials to determine the overall opti-
mal duration of treatment of hospitalised children with 
severe and very severe pneumonia. The optimal choice 
of antibiotic for oral step-down regimens is also unclear, 
specifically amoxicillin compared to agents that treat 
staphylococcal infection (such as amoxicillin clavulanate).
a number of emerging themes have been identified:
(1)the optimal dosing recommendation for amoxicillin remains unclear. 
there are concerns from recent adult pharmacokinetic data about 
twice-daily dosing in settings of high pneumococcal resistance. do 
250 mg amoxicillin dispersible tablets cover all the paediatric dosing 
requirements?
(2)it is unclear whether amoxicillin or broader-spectrum antibiotics are 
most commonly being used to treat caP in different Who regions. it 
is difficult to assess the uptake and implementation of the 2014 Who 
caP guidance
(3)there remains no globally relevant head-to-head pragmatic trial 
directly comparing the effectiveness of amoxicillin with an oral cepha-
losporin and a macrolide in the ambulatory setting
(4)the optimal antibiotic management of hospitalised children with 
severe and very severe pneumonia as well as severe pneumonia in 
older hospitalised children remains unclear
identify serotypes, resistance features, genotypes, and 
pilus types. PCV13 targeted all major 19A and 7F geno-
types, and decreased antimicrobial resistance, primarily 
owing to removal of the 19A/ST320 complex. The strain 
complex contributing most to the remaining β-lactam 
resistance during 2011–2013 was 35B/ST558. Significant 
emergence of non-vaccine clonal complexes was not evi-
dent. Because of the removal of vaccine serotype strains, 
positivity for one or both pilus types (PI-1 and PI-2) 
decreased in the post-PCV13 years 2011–2013 relative to 
2008–2009 (decreases of 32–55% for PI-1, and > 95% for 
PI-2 and combined PI-1 + PI-2). Beta-lactam susceptibility 
phenotypes correlated consistently with transpeptidase 
region sequence combinations of the three major peni-
cillin-binding proteins (PBPs) determined through WGS 
analysis. Other major resistance features were predict-
able by DNA signatures from WGS analysis. Multilocus 
sequence data combined with PBP combinations iden-
tified progeny, serotype donors and recipient strains in 
serotype switch events. PCV13 decreased the frequency 
of all PCV13 serotype clones and concurrently decreased 
the frequency of strain subsets with resistance and/or 
adherence features conducive to successful carriage [38].
Effect of PCV13 vaccine on disease severity. The link 
between disease severity and serotype in adults was 
evaluated [39]. Serotypes covered by the conjugate 
pneumococcal vaccine (Serotypes 9V, 14, 6B, 18C, 23F, 
19F, and 4) were compared to non-vaccine serotypes. No 
differences were seen in disease severity or associated 
mortality among patients infected with PCV serotypes, 
compared with patients infected with non-vaccine 
serotypes. Invasive pneumococcal disease, older age, 
underlying chronic disease, immunosuppression 
and severity of disease were significantly associated 
with mortality. No association was found between 
nosocomial infection with invasive serotypes 1, 5, and 
7 and mortality. The risk factors meningitis, suppurative 
lung complications and pre-existing lung disease 
were significantly associated with disease severity, 
independent of infecting serotype. Overall, host 
factors were more important than isolate serotype 
in determining the severity and outcome of invasive 
pneumococcal disease in adults [39].
Duration of treatment: intravenous to oral switch
Few studies are available to inform duration of intra-
venous antibiotics for children and when it is safe and 
appropriate to switch to oral antibiotics. Shorter antibi-
otic courses can potentially affect antimicrobial resist-
ances. The duration and timing of switching antibiotic 
administration from intravenous to oral in 36 paediatric 
infectious diseases has been systematically reviewed and 
recommendations developed [40]. The minimum intra-
venous and total antibiotic duration required to achieve 
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